Amphion Innovations plc
Directors Dealings

Board members receive shares in lieu of fees

7 January 2008 - Amphion Innovations plc (the “Company”), a builder of companies in life sciences and technology, announces today that Board members Richard Mansell-Jones and R. James Macaleer have, in lieu of their directors’ fee for the period 1 January to 31 December 2007, received their full remuneration in the form of ordinary shares priced at 21.5p being the closing mid market price on 2 January 2008.

Richard Mansell-Jones, Chairman of Amphion, received 164,402 ordinary shares, bringing his total holdings of the Company to 2,562,565 representing 1.99 per cent of the Company’s issued ordinary share capital. Pursuant to Rule 13 of the AIM Rules this constitutes a related party transaction and the independent Directors consider having consulted with its Nominated Adviser that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

R. James Macaleer received 82,201 ordinary shares, bringing his total holding of the Company to 19,851,449 representing 15.44 per cent of the Company’s issued ordinary share capital.

Admission of the 246,603 new ordinary shares, ranking pari passu, is expected on 11 January 2008.

For further information please contact

Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 212 210 6224

Financial Dynamics
Ben Atwell / Susan Quigley
+44 20 7831 3113

Charles Stanley Securities - Nominated Adviser
Mark Taylor / Freddy Crossley
+44 20 7149 6000

About Amphion Innovations plc
Amphion Innovations plc (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors. Amphion uses a focused, hands-on company building approach based on decades of experience in both the US and UK.

On the web: